How much funding has Neurode raised?

Neurode has raised $18.8M in total funding, most recently a Series A round.

Who are Neurode's investors?

Neurode's investors include Khosla Ventures, HAX Growth, PsyMed Ventures.

Where is Neurode headquartered?

Neurode is headquartered in Sydney, Australia.

What industry is Neurode in?

Neurode operates in Biotech, Healthcare, Medical Devices.

Neurode

Drug-free ADHD treatment you wear

Sydney, Australia · Founded 2021 · $18.8M raised

Biotech

Healthcare

Medical Devices

Headquarters: Sydney
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: neurode.com.au
Total Funding: $18.8M
Last Round: $5.3M Series AMay 2025
Rounds: 3

About

Neurode is building a wearable neurostimulation headband designed to treat and monitor ADHD through non-invasive brain stimulation, intended for 20 minutes of daily home use as a drug-free alternative. Co-founded by neuroscientist Nathalie Gouailhardou, the company combines wearable hardware with neural decoding models to understand and enhance cognitive performance. Neurode is a Pty Ltd (Australian entity) with a growing US presence, hiring in San Francisco, and is backed by venture investors. The company targets the significant unmet need for non-pharmacological ADHD interventions.

Summary

Neurode is a Biotech company based in Sydney, Australia, founded in 2021. It has raised $18.8M in total across 3 rounds, most recently a $5.3M Series A round in May 2025. Investors include Khosla Ventures, HAX Growth and PsyMed Ventures.